BioSpace News Archive

Bayer has high hopes of driving its prostate cancer drug into blockbuster status, meaning over $1 billion in annual sales. This week’s ARASENS trial results should help pave the road.

Progress continues across Canada with COVID-19 vaccination campaigns now underway in all jurisdictions for children aged 5 to 11.

Pharmascience Inc. is recalling 18 lots of over-the-counter ranitidine drugs after tests found NDMA, a nitrosamine impurity, close to and above the acceptable level.

Atara Biotherapeutics, Inc. today reported the grant of an aggregate of 21,438 restricted stock units of Atara’s common stock to seven newly hired employees and stock options to purchase an aggregate of 24,017 shares.

Precision BioSciences, Inc. today announced it will present preclinical data for its chronic hepatitis B virus (HBV) program at the HEP DART 2021 conference taking place in Cabo San Lucas, Mexico, December 5 – 9, 2021.

Pear Therapeutics, Inc. announced today the completion of its business combination with Thimble Point Acquisition Corp.

Secura Bio, Inc. (Secura Bio) - (www.securabio.com), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, has voluntarily withdrawn the U.S. COPIKTRA indication for the treatment of patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.

Today Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announced that the IC14 arm of the trial has been terminated.

Xoran Technologies announces that the first VetCAT IQ™ has been installed at an exotics-only animal hospital.

GreenLight Biosciences and IAVI, a nonprofit scientific research organization, announced work on a messenger RNA vaccine candidate to tackle the COVID-19 Omicron variant.